Schrodinger is trading at $23.50, down 9.2% in pre-market, with no verified company-specific announcement or clearly linked catalyst identified for the October 14 decline.
- Recent coverage describes mixed analyst views: TD Cowen and BMO raised price targets, while UBS cited limited near-term catalysts and slow adoption of computational drug discovery tools.
- Broader markets were mixed: S&P 500 up 0.15%, Nasdaq down 0.10%, and Dow up 0.29%; these moves do not establish a market-wide explanation.